22 reports

Tuberculosis Drugs Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 ##.

  • Pathology
  • Tuberculosis
  • APAC
  • World
  • Demand
  • 6.1.1 May 21, 2018: Oxford Immunotec's T-SPOT.TB Test Included in the World Health Organization's First-Ever Essential Diagnostics List

" Despite steady progress in reducing the burden of tuberculosis in recent decades, TB remains a major global health problem and one of the top ## causes of death worldwide, " said Dr.

  • Tuberculosis
  • United Kingdom
  • Market Size
  • DENTSPLY Sirona Inc.
  • Ivoclar Vivadent AG
  • PULMONARY TUBERCULOSIS THERAPEUTICS, GLOBAL, CLINICAL TRIALS BY PHASE (%), 2018*
  • PULMONARY TUBERCULOSIS THERAPEUTICS, GLOBAL, CLINICAL TRIALS IN PROGRESS BY PHASE, 2018*

Pulmonary Tuberculosis Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Pulmonary Tuberculosis Global Clinical Trials Review, H1, 2018" provides an overview of Pulmonary Tuberculosis clinical trials scenario.This report provides top line data relating to the clinical...

  • Anti-Infective
  • Clinical Trial
  • Tuberculosis
  • World
  • Product Initiative

The report focuses on drugs and therapies being evaluated for Mycobacterium Tuberculosis Infections treatment in active clinical development phases including phase ##, phase ##, phase ## and phase ## clinical trials.

  • Clinical Trial
  • Pathology
  • Tuberculosis
  • AERAS ENTERS INTO CO-DEVELOPMENT AGREEMENT WITH TIANJIN CANSINO FOR TUBERCULOSIS VACCINE
  • AERAS ENTERS INTO R&D AGREEMENT WITH GLAXOSMITHKLINE VACCINES TO DEVELOP TUBERCULOSIS VACCINE

Summary Aeras Global TB Vaccine Foundation Inc (Aeras) is a non-profit biotech organization that develops tuberculosis (TB) vaccines.The organization offers TB vaccine candidates, preclinical candidates and vaccine candidates. Its services include portfolio management, preclinical research, clinical trials, research...

  • Pathology
  • Pharmaceutical
  • Tuberculosis
  • Vaccine
  • World
  • May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
  • May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2018 Summary DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2018, outlays comprehensive information on the DNA Gyrase Subunit B...

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • Spero Therapeutics, LLC
  • Infectex Enters Into Licensing Agreement With Qurient For Tuberculosis Drug Q203
  • Jun 22, 2017: Infectex Successfully Completes Phase 1 Clinical Study of Q203 for Treatment of Tuberculosis

Summary Qurient Co Ltd (Qurient) is a pharmaceutical company that offers development of new drugs for unmet medical needs.The company provides portfolio of pipeline products such as Q301, Q203, Q701, 5LO INH and CDK7 INH, among others. It is developing products for the treatment of atopic dermatitis; extensively...

  • Pharmaceutical
  • Tuberculosis
  • South Korea
  • Company
  • Qurient Co., Ltd.
  • SANOFI ENTERS INTO RESEARCH AGREEMENT WITH TB ALLIANCE TO ADVANCE TREATMENTS FOR TUBERCULOSIS
  • NOVARTIS ENTERS INTO LICENSING AGREEMENT WITH GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT FOR TUBERCULOSIS DRUGS

Summary Global Alliance for TB Drug Development (TB Alliance) is a non-profit organization that discovers and develops drugs to treat tuberculosis.The organization’s products include natural products, rifampin, pyrazinamide, isoniazid, macrokuds, ethambutol, and topoisomerase inhibitors. It offers biomakers and lab...

  • Pathology
  • Tuberculosis
  • World
  • Company
  • TB Drug Development, Inc.
  • VENTURE FINANCING
  • Sequella Enters Into Licensing Agreement With Pfizer For Sutezolid

SQ## could replace one or more of the current TB drugs, simplify therapy, and shorten current treatment time.

  • Tuberculosis
  • Russia
  • United States
  • World
  • Deals & Alliance
  • Mar 24, 2018: Multidisciplinary Consortium Announces Launch of PITBUL, an International Collaboration for the Development of Ultrafast Tuberculosis Diagnostics
  • PITBUL ULTRAFAST TB TEST - PRODUCT DESCRIPTION

Summary GNA Biosolutions GmbH (GNAB) is an assays and instruments development company that develops assays and instruments for ultra-fast molecular pathogen detection of biomolecules through its technology.The company also develops rapid diagnostic DNA-based laser-heated nanoparticles. It uses PCR (Polymerase Chain...

  • Antibiotic Resistance
  • In Vitro Diagnostics
  • Tuberculosis
  • Company
  • Product Initiative
  • Function
  • AVISA PHARMA INC PIPELINE PRODUCTS BY INDICATION

Summary Avisa Pharma Inc (Avisa Pharma) is a medical device company that develops breath tests system for the diagnosis of pulmonary infections.The company provides product such as avisa breath test kit, which is designed to detect respiratory bacterial infections in the lung and other metabolic diseases; and avisar spec,...

  • Pathology
  • Tuberculosis
  • United States
  • Product Initiative
  • Avisa Pharma Inc.
  • TNP-2092 - DRUG PROFILE

In September 2006, Cumbre Pharmaceuticals Inc has entered into agreement with Global Alliance for TB Drug Development, a non-profit product development partnership for new tuberculosis (TB) drugs, to develop new agents for tuberculosis therapy.

  • Tuberculosis
  • United States
  • World
  • Product Initiative
  • AmpliPhi Biosciences Corporation
  • Mar 12, 2018: Molecular doorstop could be key to new tuberculosis drugs

Summary Rockefeller University (Rockefeller) is a biomedical research university that offers graduate and postdoctoral educational programs.The university offers educational courses in the fields of biomedical sciences, chemistry, bioinformatics and physics. It conducts clinical studies in the areas of addictive...

  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United States
  • Company
  • Feb 07, 2017: Researchers use tiny 3-D spheres to combat tuberculosis
  • Feb 07, 2017: Researchers use tiny 3-D spheres to combat tuberculosis

Summary University of Southampton (UOS) is an educational institution that offers education and research services.The institute provides educational programs in the fields of accounting and finance, acoustical engineering, aeronautics and astronautics, anthropology, archaeology, biochemistry, biology, biomedical sciences,...

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Tuberculosis
  • United Kingdom
  • Indication
  • Technology

Summary Wave 80 Biosciences Inc (Wave 80) is a medical device company that develops molecular diagnostic instruments and consumables.The company develops molecular diagnostics instruments for chlamydia, respiratory illness, cancers, autoimmune diseases, hepatitis B, hepatitis C, HIV/AIDS and other human health conditions. It...

  • Medical Device
  • Tuberculosis
  • United States
  • Company
  • Product Initiative
  • Oxford Immunotec Enters Into Licensing Agreement With Lophius Biosciences For T-Spot Technology
  • Oxford Immunotec Enters Into Licensing Agreement With Lophius Biosciences For Urea Technology

Revenue for the first quarter of 2018 was $##. ## million, representing a ##% decrease from first quarter 2017 revenue of $##. ## million.

  • Tuberculosis
  • United States
  • Company
  • Company Financials
  • Market Size
  • MAY 21, 2018: OXFORD IMMUNOTEC'S T-SPOT.TB TEST INCLUDED IN THE WORLD HEALTH ORGANIZATION'S FIRST-EVER ESSENTIAL DIAGNOSTICS LIST
  • JUN 22, 2017: OXFORD IMMUNOTEC ANNOUNCES NATIONAL REIMBURSEMENT FOR THE T-SPOT.TB TEST IN FRANCE

" Despite steady progress in reducing the burden of tuberculosis in recent decades, TB remains a major global health problem and one of the top ## causes of death worldwide, " said Dr.

  • Infectious Disease
  • Tuberculosis
  • United States
  • World
  • Market Size
  • PARTNERSHIPS
  • PARTNERSHIPS

Summary Sequella Inc (Sequella) is a clinical-stage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections.The company’s pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, B-SMART. Sequella develops...

  • Pathology
  • Tuberculosis
  • United States
  • Deals & Alliance
  • QIAGEN N.V.: NEWS AND EVENTS SUMMARY

The company operates in one business segment.

  • Molecular Diagnostic
  • Tuberculosis
  • United States
  • Company
  • QIAGEN N.V.
  • BIOVERSYS ENTERS INTO AGREEMENT WITH GLAXOSMITHKLINE AND UNIVERSITY OF LILLE
  • PARTNERSHIPS

Summary Bioversys AG (Bioversys) is a biotechnology company that researches and develops small molecules which turn off drug resistance against existing antibiotics.The company employs proprietary transcriptional regulator inhibitory compounds (TRIC) technology for screening, identifying and developing molecules for restoring...

  • Tuberculosis
  • Switzerland
  • United States
  • Deals & Alliance
  • Bioversys
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS ENTERS INTO AGREEMENT WITH MOLBIO DIAGNOSTICS
  • FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS ENTERS INTO AGREEMENT WITH CEPHEID AND RUTGERS

The timeline of development is from April 2016 through October 2017, for one year and seven months.

  • Diagnostics
  • Tuberculosis
  • Switzerland
  • United States
  • Deals & Alliance
  • Dec 22, 2017: TB-LAMP was Listed in the Catalog of GDF

Summary Eiken Chemical Co Ltd (Eiken Chemical), a subsidiary of Hitachi High-Technologies Corp is a medical equipment provider that offers molecular genetic products and medical devices.The company manufactures and markets clinical diagnostics and equipment, among others. It also provides fecal immunochemical test,...

  • Tuberculosis
  • Japan
  • United Kingdom
  • Company
  • Eiken Chemical Co., Ltd.